Wir sind mit live! Mehr erfahren

OrthoPediatrics

KIDS

Börsenwert 573 Mio. $

21,95 USD

-0,62

2,75 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

21,95

0,00

0 %

1 Tag

-2,75 %

5 Tage

1,62 %

1 Monat

-5,18 %

3 Monate

7,7 %

6 Monate

32,79 %

Seit Jahresbeginn

25 %

1 Jahr

23,31 %

5 Jahre

-64,09 %

10 Jahre

14,2 %

Profil: OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.

Mitarbeiter: 602

Gesundheitswesen Medizintechnik

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 8,3 %

Neutral 75 %

Negativ 16,7 %

OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 27, 2026

WARSAW, Ind., Oct. 13, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its third quarter 2026 financial results on Tuesday, October 27, 2026 after the market closes. OrthoPediatrics will host a conference call on Tuesday, October 27, 2026 at 4:30 p.m. ET to discuss the results.

OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 27, 2026

OrthoPediatrics Expands Its Lower Extremity Bracing Portfolio with the Launch of OPSB® Knee 'TractorFIX

WARSAW, Ind., Oct. 07, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its OrthoPediatrics Specialty Bracing (“OPSB”) portfolio with a new product launch, the OPSB® Knee 'TractorFIX contracture management orthosis.

OrthoPediatrics Expands Its Lower Extremity Bracing Portfolio with the Launch of OPSB® Knee 'TractorFIX

OrthoPediatrics Sponsors the 10th Pediatric Orthopedic Surgical Techniques Course

Milestone program with record attendance brought together 39 participants from 23 institutions across 22 cities and three countries Milestone program with record attendance brought together 39 participants from 23 institutions across 22 cities and three countries

OrthoPediatrics Sponsors the 10th Pediatric Orthopedic Surgical Techniques Course

OrthoPediatrics Surpasses 1,000 PNP Tibia Nail Implantations

WARSAW, Ind., Sept. 22, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the recent implantation of the 1,000th Tibia Nail using its latest Pediatric Nailing Platform (PNP).

OrthoPediatrics Surpasses 1,000 PNP Tibia Nail Implantations

OrthoPediatrics Announces Full Commercial Launch of 3P™ Pediatric Plating Platform® Hip System Following More Than 350 Successful Implantations

Successful Limited Launch Demonstrates Demand for Innovative Pediatric-Specific Hip Plating Technology Successful Limited Launch Demonstrates Demand for Innovative Pediatric-Specific Hip Plating Technology

OrthoPediatrics Announces Full Commercial Launch of 3P™ Pediatric Plating Platform® Hip System Following More Than 350 Successful Implantations

OrthoPediatrics Sees ‘Inflection Point' as New Products Fuel Record Quarter

OrthoPediatrics NASDAQ: KIDS reported record revenue, adjusted EBITDA and number of children helped during the second quarter, as the pediatric orthopedic device company began to see early contributions from its newer “super cycle” products, Chief Executive Officer Dave Bailey said at the Canaccord Genuity Growth Conference.

OrthoPediatrics Sees ‘Inflection Point' as New Products Fuel Record Quarter

OrthoPediatrics Corp. (KIDS) Q2 2026 Earnings Call Transcript

OrthoPediatrics Corp. (KIDS) Q2 2026 Earnings Call Transcript

OrthoPediatrics Corp. (KIDS) Q2 2026 Earnings Call Transcript

OrthoPediatrics Q2 Earnings Call Highlights

OrthoPediatrics NASDAQ: KIDS reported record second-quarter revenue of $70.5 million, up 15% from a year earlier, as strong Trauma & Deformity and specialty bracing performance offset a reported decline in scoliosis revenue. The company also raised its 2026 revenue outlook while maintaining its adjusted EBITDA and free-cash-flow targets.

OrthoPediatrics Q2 Earnings Call Highlights

Zacks Investment Research

OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates

OrthoPediatrics (KIDS) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.11 per share a year ago.

OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates

OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance

WARSAW, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the second quarter ended June 30, 2026.

OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt